File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors

TitlePalbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors
Authors
KeywordsBreast cancer
CDK4/6 inhibitor
palbociclib
practical guidance
endocrine therapy
Issue Date2020
PublisherTaylor and Francis. The Journal's web site is located at http://informahealthcare.com/journal/cmo/
Citation
Current Medical Research and Opinion, 2020, v. 36 n. 8, p. 1363-1373 How to Cite?
AbstractBreast cancer is the most frequent cancer amongst women worldwide including in Asia where the incidence rate is rapidly increasing. Even with treatment, around 30% of patients with early breast cancer progress to metastatic disease, with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer the most common phenotype. First-line endocrine therapy targeting the estrogen receptor signaling pathway provides a median progression-free survival or time to progression of 6–15 months in HR + HER2- metastatic breast cancer. Recently, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, combined with endocrine therapy, have achieved more than two years median progression-free survival in HR + HER2- metastatic breast cancer. However, the characteristics of the Asian breast cancer population differ from those of Western populations and need to be considered when selecting a suitable treatment. Breast cancer is diagnosed at a younger age in Asian populations and late stage at presentation is generally more common in low-/middle-income countries than high-income countries. Consequently, the proportion of premenopausal women with metastatic breast cancer is higher in Asian compared with Western populations. While CDK4/6 inhibitors have been approved in the USA (FDA) since 2015, experience with them in Asia is more limited. We review the experience with the CDK4/6 inhibitor palbociclib in Asian patients with HR + HER2- metastatic breast cancer and provide guidance on the use of palbociclib in these patients.
Persistent Identifierhttp://hdl.handle.net/10722/293814
ISSN
2023 Impact Factor: 2.4
2023 SCImago Journal Rankings: 0.712
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDawood, S-
dc.contributor.authorChiu, JWY-
dc.contributor.authorHuang, CS-
dc.contributor.authorNag, S-
dc.contributor.authorSookprasert, A-
dc.contributor.authorYap, YS-
dc.contributor.authorMd Yusof, M-
dc.date.accessioned2020-11-23T08:22:10Z-
dc.date.available2020-11-23T08:22:10Z-
dc.date.issued2020-
dc.identifier.citationCurrent Medical Research and Opinion, 2020, v. 36 n. 8, p. 1363-1373-
dc.identifier.issn0300-7995-
dc.identifier.urihttp://hdl.handle.net/10722/293814-
dc.description.abstractBreast cancer is the most frequent cancer amongst women worldwide including in Asia where the incidence rate is rapidly increasing. Even with treatment, around 30% of patients with early breast cancer progress to metastatic disease, with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer the most common phenotype. First-line endocrine therapy targeting the estrogen receptor signaling pathway provides a median progression-free survival or time to progression of 6–15 months in HR + HER2- metastatic breast cancer. Recently, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, combined with endocrine therapy, have achieved more than two years median progression-free survival in HR + HER2- metastatic breast cancer. However, the characteristics of the Asian breast cancer population differ from those of Western populations and need to be considered when selecting a suitable treatment. Breast cancer is diagnosed at a younger age in Asian populations and late stage at presentation is generally more common in low-/middle-income countries than high-income countries. Consequently, the proportion of premenopausal women with metastatic breast cancer is higher in Asian compared with Western populations. While CDK4/6 inhibitors have been approved in the USA (FDA) since 2015, experience with them in Asia is more limited. We review the experience with the CDK4/6 inhibitor palbociclib in Asian patients with HR + HER2- metastatic breast cancer and provide guidance on the use of palbociclib in these patients.-
dc.languageeng-
dc.publisherTaylor and Francis. The Journal's web site is located at http://informahealthcare.com/journal/cmo/-
dc.relation.ispartofCurrent Medical Research and Opinion-
dc.subjectBreast cancer-
dc.subjectCDK4/6 inhibitor-
dc.subjectpalbociclib-
dc.subjectpractical guidance-
dc.subjectendocrine therapy-
dc.titlePalbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors-
dc.typeArticle-
dc.identifier.emailChiu, JWY: jwychiu@hku.hk-
dc.identifier.authorityChiu, JWY=rp01917-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/03007995.2020.1783646-
dc.identifier.pmid32544344-
dc.identifier.scopuseid_2-s2.0-85087624739-
dc.identifier.hkuros319594-
dc.identifier.volume36-
dc.identifier.issue8-
dc.identifier.spage1363-
dc.identifier.epage1373-
dc.identifier.isiWOS:000547486300001-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0300-7995-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats